scholarly journals DC-based Vacccine for Intrahepatic Cholangiocellular Carcinoma

2012 ◽  
Vol 37 (1) ◽  
pp. 50-55
Author(s):  
Yoshihito Kotera ◽  
Syuniti Ariizumi ◽  
Yutaka Takahasi ◽  
Takaaki Kato ◽  
Godai Yoneda ◽  
...  
Keyword(s):  
Cholangiocellular Carcinoma ◽  
Intrahepatic Cholangiocellular Carcinoma

A pilot study on cisplatin-based transarterial chemoembolization combined with systemic cisplatin plus gemcitabine for advanced or metastatic intrahepatic cholangiocellular carcinoma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e15629-e15629
Author(s):  
Sadahisa Ogasawara ◽  
Yoshihiko Ooka ◽  
Eiichiro Suzuki ◽  
Harutoshi Sugiyama ◽  
Akinobu Tawada ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Adverse Events ◽  
Transarterial Chemoembolization ◽  
Group Performance ◽  
Objective Response ◽  
Eastern Cooperative Oncology Group ◽  
Cholangiocellular Carcinoma ◽  
Gelatin Sponge ◽  
Treatment Schedule ◽  
Intrahepatic Cholangiocellular Carcinoma

e15629 Background: Systemic cisplatin plus gemcitabine (CisGem) is the standard treatment for patients with advanced or metastatic intrahepatic cholangiocellular carcinoma (ICC). Transarterial chemoembolization (TACE) is a treatment procedure for patients with liver cancer. This prospective study was to evaluate the safety and efficacy of cisplatin-based TACE combined with systemic CisGem in patients with ICC. Methods: Eligibility criteria were histologically or cytologically confirmed, unresectable, recurrent or metastatic mass-forming type ICC; Eastern Cooperative Oncology Group performance status 0–2; and an adequate major organ function. Patients may have had prior treatment, including surgery, but no prior CisGem therapy. Cisplatin (25 mg/m2) plus gemcitabine (1000 mg/m2) were intravenously administered on days 1 and 8 of a 21-day cycle for 12 cycles. Three sessions of TACE were scheduled—before first, fifth, and ninth cycle of CisGem. A suspension of CDDP-powder 35 mg/m2 and lipiodol was injected through tumor-feeding branch of intrahepatic lesions, and embolization of the feeding arteries was performed using gelatin sponge (UMIN000004776). Results: Of 14 patients enrolled between December 2010 and December 2013, 7 (50%) completed treatment schedule, whereas 4 (29%) and 3 (21%) discontinued due to disease progression and adverse events (one patients each due to allergic reaction, platelet count reduction, and hepatic infection), respectively. The most common severe adverse events were elevated aspartate aminotransferase (86%) and alanine aminotransferase (71%) levels; reduced neutrophil (36%), platelet (36%), and white blood cell (28%) counts; and hepatic infection (21%). Eleven patients (79%) were evaluated for objective response (RECIST version 1.1): 9 were observed to have a partial response and 2 had a stable disease. The 6-month progression-free survival rate was 64%, and median overall survival was 25.8 months. Conclusions: Cisplatin-based TACE combined with CisGem is a feasible treatment option; however, a randomized clinical trial for comparison with CisGem is required in future. Clinical trial information: UMIN000004776.

Clinicopathological characteristics of intrahepatic cholangiocellular carcinoma presenting intrahepatic bile duct growth

2008 ◽  
Vol 99 (3) ◽  
pp. 161-165 ◽  
Author(s):  
Yusuke Yamamoto ◽  
Kazuaki Shimada ◽  
Yoshihiro Sakamoto ◽  
Minoru Esaki ◽  
Satoshi Nara ◽  
...  
Keyword(s):  
Bile Duct ◽  
Intrahepatic Bile Duct ◽  
Clinicopathological Characteristics ◽  
Cholangiocellular Carcinoma ◽  
Intrahepatic Cholangiocellular Carcinoma

Blockage of CXCR2 suppresses tumor growth of intrahepatic cholangiocellular carcinoma

Surgery ◽  
2014 ◽  
Vol 155 (4) ◽  
pp. 640-649 ◽  
Author(s):  
Hideaki Sueoka ◽  
Tadamichi Hirano ◽  
Yugo Uda ◽  
Yuji Iimuro ◽  
Junichi Yamanaka ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Cholangiocellular Carcinoma ◽  
Intrahepatic Cholangiocellular Carcinoma

scholarly journals A case of intrahepatic cholangiocellular carcinoma with sarcomatous change

Kanzo ◽  
2010 ◽  
Vol 51 (9) ◽  
pp. 521-527 ◽  
Author(s):  
Koichiro Yasuda ◽  
Takefumi Niguma ◽  
Toshiyuki Takagi ◽  
Shinichi Fujioka ◽  
Toshiya Osawa ◽  
...  
Keyword(s):  
Cholangiocellular Carcinoma ◽  
Sarcomatous Change ◽  
Intrahepatic Cholangiocellular Carcinoma

scholarly journals A case of intrahepatic cholangiocellular carcinoma due to Thorotrast deposition, well-controlled by radiofrequency ablation therapy

Kanzo ◽  
2020 ◽  
Vol 61 (5) ◽  
pp. 262-269
Author(s):  
Nobuhito Taniki ◽  
Nobuhiro Nakamoto ◽  
Aya Yoshida ◽  
Po-Sung Chu ◽  
Akihiko Ikura ◽  
...  
Keyword(s):  
Radiofrequency Ablation ◽  
Cholangiocellular Carcinoma ◽  
Ablation Therapy ◽  
Intrahepatic Cholangiocellular Carcinoma ◽  
Radiofrequency Ablation Therapy
Sign in / Sign up

Export Citation Format

Share Document